Y Wang1, C Shen2, J Ge3, H Duan4. 1. Department of Surgery, Liaoning Cancer Hospital and Institute, Shenyang, China. Electronic address: 13514212975@163.com. 2. Department of Surgery, The Second Hospital of Shenyang Medical College, Shenyang, China. Electronic address: chunjianshen@sina.com. 3. Department of Surgery, The First Hospital of China Medical University, Shenyang, China. Electronic address: jianniange@126.com. 4. Department of Epidemiology, Zhengzhou University, Zhengzhou, China. Electronic address: hongduan@126.com.
Abstract
OBJECTIVE: Epidemiological studies on aspirin and stomach cancer have been inconclusive. The purpose of our study was to investigate the association between aspirin and stomach cancer in China. METHOD: A 1:2 matched case-control study was conducted in four large medical centers. A self-designed questionnaire was used to collect information. Unconditional logistic regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). RESULT: Our study indicated that risk of stomach cancer was greatly reduced for regular aspirin user (OR = 0.62; 95% CI 0.42-0.80). Specifically, dosage and tablet-years of use were associated with lower risk (OR = 0.54; 95% CI 0.29-0.84 for ≥7 tabs/week; OR = 0.47; 95% CI 0.32-0.81 for ≥10 tablet years, respectively). Furthermore, the finding was strengthened by stratified studies of gender, smoking status, body mass index (BMI) and helicobacter pylori. CONCLUSION: Our study confirmed that regular aspirin use is a protective factor to stomach cancer.
OBJECTIVE: Epidemiological studies on aspirin and stomach cancer have been inconclusive. The purpose of our study was to investigate the association between aspirin and stomach cancer in China. METHOD: A 1:2 matched case-control study was conducted in four large medical centers. A self-designed questionnaire was used to collect information. Unconditional logistic regression was used to compute crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs). RESULT: Our study indicated that risk of stomach cancer was greatly reduced for regular aspirin user (OR = 0.62; 95% CI 0.42-0.80). Specifically, dosage and tablet-years of use were associated with lower risk (OR = 0.54; 95% CI 0.29-0.84 for ≥7 tabs/week; OR = 0.47; 95% CI 0.32-0.81 for ≥10 tablet years, respectively). Furthermore, the finding was strengthened by stratified studies of gender, smoking status, body mass index (BMI) and helicobacter pylori. CONCLUSION: Our study confirmed that regular aspirin use is a protective factor to stomach cancer.